Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,924,807
  • Shares Outstanding, K 79,257
  • Annual Sales, $ 806,780 K
  • Annual Income, $ -363,300 K
  • EBIT $ 886 M
  • EBITDA $ 1,110 M
  • 60-Month Beta 0.50
  • Price/Sales 4.79
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 50.56% ( -5.43%)
  • Historical Volatility 23.90%
  • IV Percentile 17%
  • IV Rank 14.24%
  • IV High 128.79% on 04/24/25
  • IV Low 37.57% on 06/20/25
  • Put/Call Vol Ratio 0.04
  • Today's Volume 143
  • Volume Avg (30-Day) 287
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 8,996
  • Open Int (30-Day) 8,748

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.07
  • Number of Estimates 8
  • High Estimate -0.62
  • Low Estimate -1.52
  • Prior Year -1.16
  • Growth Rate Est. (year over year) +7.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.40 +2.37%
on 07/07/25
52.45 -7.48%
on 06/17/25
-2.29 (-4.52%)
since 06/11/25
3-Month
35.95 +34.98%
on 05/06/25
52.98 -8.40%
on 06/06/25
+5.55 (+12.90%)
since 04/11/25
52-Week
29.01 +67.24%
on 08/09/24
58.38 -16.88%
on 03/17/25
+15.33 (+46.16%)
since 07/11/24

Most Recent Stories

More News
PTC Therapeutics: Q1 Earnings Snapshot

PTC Therapeutics: Q1 Earnings Snapshot

PTCT : 48.59 (-1.88%)
PTC Therapeutics (PTCT) Q1 2025 Earnings Call

PTC Therapeutics, Inc. (NASDAQ:PTCT) reported $190 million in first-quarter revenue, primarily driven by its Duchenne muscular dystrophy (DMD) franchise. The company narrowed its 2025 full-year revenue...

PTCT : 48.59 (-1.88%)
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 48.59 (-1.88%)
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows

Wells Fargo highlighted the agreement’s $1.9 billion milestone potential, 40% U.S. profit-sharing terms, and double-digit royalties on ex-U.S. sales.

PTCT : 48.59 (-1.88%)
NVS : 120.91 (-2.28%)
PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 48.59 (-1.88%)
3 Top Stocks That Could Still Rocket Higher in 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

PTCT : 48.59 (-1.88%)
VRTX : 470.85 (-1.81%)
BBIO : 46.30 (+0.06%)
RHHBY : 40.5600 (-1.60%)
PFE : 25.63 (-0.58%)
PTC Therapeutics: Q2 Earnings Snapshot

PTC Therapeutics: Q2 Earnings Snapshot

PTCT : 48.59 (-1.88%)
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

Stocks that traded heavily or had substantial price changes on Friday: Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise

PTCT : 48.59 (-1.88%)
PTGX : 53.38 (+1.04%)
KRUS : 74.40 (+0.03%)
FCX : 45.94 (-2.69%)
ACCD : 7.02 (-0.14%)
INFN : 6.64 (-0.15%)
PTC Therapeutics: Q1 Earnings Snapshot

PTC Therapeutics: Q1 Earnings Snapshot

PTCT : 48.59 (-1.88%)
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 48.59 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 51.64
2nd Resistance Point 50.69
1st Resistance Point 50.10
Last Price 48.59
1st Support Level 48.56
2nd Support Level 47.61
3rd Support Level 47.02

See More

52-Week High 58.38
Last Price 48.59
Fibonacci 61.8% 47.16
Fibonacci 50% 43.70
Fibonacci 38.2% 40.23
52-Week Low 29.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar